CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NeurogesX, Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NeurogesX, Inc
2215 Bridgepointe Parkway
Suite 200
Phone: (302) 658-7581p:302 658-7581 Foster City, CA  94404-5067  United States Ticker: NGSX NGSX
This company is no longer actively traded on any major stock exchange.
Business Summary
NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pains management therapies to address unmet medical needs. Qutenza is the Company's first commercial product, available in the United States and in certain European countries. Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions and was approved by the food and drugs administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia (PHN). Qutenza is also approved in the European Union for the treatment of peripheral neuropathic pain in non-diabetic adults. The Company's advanced drug candidate is NGX-1998. NGX-1998 is a topical liquid formulation of high concentration capsaicin that the Company is developing to treat neuropathic pain conditions.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201212/31/2011YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Gary A.Lyons 62 4/27/2011 4/27/2011
President, Chief Executive Officer, Director Ronald A.Martell 50 1/1/2012 1/1/2012
Chief Financial Officer, Chief Operating Officer, Executive Vice President Stephen F.Ghiglieri 50 1/1/2010 10/1/2003
6 additional Officers and Directors records available in full report.

Business Names
Business Name
NeurogesX Inc
NeurogesX Inc.
NeurogesX UK Limited
NeurogesX, Inc
NeurogesX, Inc.
NGSX

General Information
Number of Employees: 35 (As of 3/15/2012)
Outstanding Shares: 33,329,119 (As of 9/30/2012)
Shareholders: 48
Stock Exchange: OTC
Federal Tax Id: 943307935
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023